UK ad review
This article was originally published in The Tan Sheet
The UK's Medicines & Healthcare products Regulatory Agency will review promotional materials for all newly licensed medicines before the advertisements are run, the agency announces Nov. 8. While MHRA previously only reviewed ads for some new ads based on risk, vetting advertising material on all new drugs allows the agency to "provide an additional safeguard to ensure that healthcare professionals and the public are not misled." Review time for promotional materials is expected to last between three and six months "but could take longer should any problems be identified," the agency stated. In the U.S., direct-to-consumer advertising guidelines released in August by the Pharmaceutical Research & Manufacturers of America called for manufacturers to submit advertising materials to FDA prior to launch (1"The Tan Sheet" Aug. 22, 2005, p. 7). EU legislation prohibits direct-to-consumer advertising for conditions including insomnia, diabetes and other metabolic diseases, serious infectious diseases including HIV-related diseases and tuberculosis...
You may also be interested in...
Pfizer direct-to-consumer prescription drug ads will "clearly indicate... that the medicine is a prescription medicine," the firm said in an Aug. 11 announcement of planned DTC changes
Biocon has made two key appointments to the management team of Biocon Biologics following a recent change in CEO for the biosimilars business.
The UK's Optibac responds to sustainability and naturals trends with an all-in-one immunity and gut health food supplement especially designed for children.